TITLE:
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

CONDITION:
Meningitis, Cryptococcal

INTERVENTION:
Fluconazole

SUMMARY:

      To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal
      meningitis in AIDS patients. Both newly diagnosed and relapsed patients are eligible.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Antiviral therapy such as zidovudine.

          -  Prophylaxis for Pneumocystis carinii pneumonia.

          -  Aerosolized pentamidine.

        Concurrent Treatment:

        Allowed:

          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.

        Written informed consent must be obtained for each patient, either from the patient
        himself or from the patient's legal guardian.

          -  No prior systemic antifungal therapy for cryptococcosis.

          -  Success of prior therapy must have been documented by negative cerebrospinal fluid
             (CSF) culture at the end of therapy. Following prior therapy, such patients may not
             have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into
             study.

        Prior Medication:

        Allowed:

          -  Antiviral therapy such as zidovudine.

          -  Prophylaxis for Pneumocystis carinii pneumonia.

          -  Aerosolized pentamidine.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  Evidence of acute or chronic meningitis based upon any etiology other than
             cryptococcosis.

          -  History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.

          -  Moderate or severe liver disease defined by specified lab values.

          -  Patients who are unable to take oral medication.

          -  Unlikely to survive more than 2 weeks.

          -  Renal impairment.

        Concurrent Medication:

        Excluded:

          -  Coumarin-type anticoagulants.

          -  Oral hypoglycemics.

          -  Barbiturates.

          -  Phenytoin.

          -  Immunostimulants.

          -  Investigational drugs or approved (licensed) drugs for investigational indications
             other than aerosolized pentamidine.

          -  Excluded within 4 weeks of study entry:

          -  Greater than 1 mg/kg/wk amphotericin B.

          -  Any exceptions to these prohibitions of concomitant medications must be approved by
             Pfizer Central Research.

        Concurrent Treatment:

        Excluded:

          -  Lymphocyte replacement.

        Patients with the following are excluded:

          -  Evidence of acute or chronic meningitis based upon any etiology other than
             cryptococcosis.

          -  History of allergy to or intolerance of imidazoles or azoles.

          -  Moderate or severe liver disease defined by specified lab values.

          -  Patients who are unable to take oral medication.

          -  Life expectancy of < 2 weeks.

          -  Any condition that may impair absorption of oral medication.

        Prior Medication:

        Excluded:

          -  Coumarin-type anticoagulants.

          -  Oral hypoglycemics.

          -  Barbiturates.

          -  Phenytoin.

          -  Immunostimulants.

          -  Investigational drugs or approved (licensed) drugs for investigational indications
             other than aerosolized pentamidine.

          -  Excluded within 4 weeks of study entry:

          -  Greater than 1 mg/kg/wk amphotericin B.

        Prior Treatment:

        Excluded:

          -  Lymphocyte replacement.
      
